Company Filing History:
12 out of 541 
Years Active: 2016-2025
Title: Sandrine Guillard: Innovator in Combination Therapies
Introduction
Sandrine Guillard is a prominent inventor based in Cambridge, GB. She has made significant contributions to the field of biomedical research, particularly in the development of combination therapies for various diseases. With a total of 11 patents to her name, her work has the potential to impact the treatment landscape for patients.
Latest Patents
Among her latest patents is a groundbreaking disclosure on combination therapies using anti-pseudomonas PSL and PCRV binding molecules. This patent relates to therapies that comprise anti-Psl and PcrV binding molecules, aimed at preventing and treating infections. Another notable patent focuses on binding molecules specific for CD73 and their uses. This disclosure provides anti-CD73 binding molecules, including antibodies and their fragments, along with pharmaceutical formulations for diagnosing and treating diseases associated with CD73 expression, such as cancer. These therapies can be administered in various ways, including direct therapy with anti-CD73 binding molecules and combination therapies with other anticancer agents.
Career Highlights
Sandrine Guillard is currently associated with Medimmune Limited, where she continues to innovate and develop new therapeutic solutions. Her work is characterized by a strong focus on addressing unmet medical needs through her inventive approaches.
Collaborations
Some of her notable coworkers include Ralph Raymond Minter and Melissa Marie Damschroder, who contribute to her research endeavors and collaborative projects.
Conclusion
Sandrine Guillard's contributions to the field of combination therapies exemplify her commitment to advancing medical science. Her innovative patents and collaborative efforts position her as a key figure in the ongoing fight against complex diseases.